Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02340975 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 114
- Enrollment target
NCT02340975 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 114 participants.
The verdict
NCT02340975, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 114 participants
- Enrollment target
Study Summary
This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab, MEDI4736 monotherapy or tremelimumab monotherapy in participants with metastatic or recurrent gastric or gastroesophageal junction adenocarcinoma.
Interventions
- BIOLOGICAL Tremelimumab
- BIOLOGICAL MEDI4736
- BIOLOGICAL MEDI4736 + tremelimumab
- BIOLOGICAL MEDI4736+tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2015-03-31 |
| Est. Completion | 2019-04-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02340975
The ClinicalTrials.gov registry entry for NCT02340975 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Tremelimumab is the first listed.
NCT02340975 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02340975 about?
NCT02340975 is a clinical study titled "A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma". This is a randomized, multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab, MEDI4736 monotherapy or tremelimumab monotherapy in participants w...
What is the current status of trial NCT02340975?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2015-03-31. Estimated completion is 2019-04-29.
What interventions are being tested in trial NCT02340975?
The interventions under investigation include: Tremelimumab (BIOLOGICAL), MEDI4736 (BIOLOGICAL), MEDI4736 + tremelimumab (BIOLOGICAL), MEDI4736+tremelimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02340975?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.